ABSTRACT: Fragment-based lead discovery (FBLD) holds great promise for drug discovery, but applications to G protein-coupled receptors (GPCRs) have been limited by a lack of sensitive screening techniques and scarce structural information. If virtual screening against homology models of GPCRs could be used to identify fragment ligands, FBLD could be extended to numerous important drug targets and contribute to efficient lead generation. Access to models of multiple receptors may further enable the discovery of fragments that bind specifically to the desired target. To investigate these questions, we used molecular docking to screen >500 000 fragments against homology models of the A 3 and A 1 adenosine receptors (ARs) with the goal to discover A 3 AR-selective ligands. Twenty-one fragments with predicted A 3 AR-specific binding were evaluated in live-cell fluorescence-based assays; of eight verified ligands, six displayed A 3 /A 1 selectivity, and three of these had high affinities ranging from 0.1 to 1.3 μM. Subsequently, structure-guided fragment-to-lead optimization led to the identification of a >100-fold-selective antagonist with nanomolar affinity from commercial libraries. These results highlight that molecular docking screening can guide fragment-based discovery of selective ligands even if the structures of both the target and antitarget receptors are unknown. The same approach can be readily extended to a large number of pharmaceutically important targets.
■ INTRODUCTION
Fragment-based lead discovery (FBLD) has rapidly developed into one of the main strategies for early-phase drug development. Drug discovery programs driven by FBLD have quickly progressed into clinical trials, and fragment screens have been applied successfully to targets for which high-throughput screening (HTS) approaches have failed. 1 The main difference between HTS and FBLD is that the latter approach initially focuses on the identification of ligands that are less than half the size of a drug. Because of the lower complexity of fragments compared with drug-like molecules, screens of chemical libraries with hundreds to thousands of compounds cover sufficient portions of chemical space to identify ligands. This makes FBLD an attractive alternative to HTS, which may require screening of libraries that are several orders of magnitude larger to identify lead compounds. 1 As fragments are typically low-affinity ligands, a major challenge in FBLD has been the development of sensitive screening techniques. This has been particularly problematic for membrane proteins, which include important drug targets such as G protein-coupled receptors (GPCRs) and ion channels. 2 Recently, fragment screens using NMR-, 3 surface plasmon resonance (SPR)-, 4 and fluorescence-based 5 methods have successfully been applied to GPCRs, making it feasible to begin utilizing FBLD for the large number of important drug targets in this superfamily. 6 The weakly binding ligands that emerge from fragment screens occupy subpockets on the protein surface and have to be combined or grown to generate potent lead compounds. 7 Fragments typically lack specificity because of their low molecular complexity, 8 which makes it a challenge to achieve selectivity for the desired target. 9 The identification of selective lead compounds is of particular importance for GPCRs, as many subtypes recognize the same ligands, resulting in orthosteric binding sites with a high degree of homology. For many soluble targets, FBLD can often take advantage of the relative ease of generating crystal structures for protein− fragment complexes, which can provide invaluable information in ligand optimization. 10 Recent breakthroughs in this area have resulted in atomic-resolution crystal structures for GPCRs, 11 and in a few cases it has even been feasible to resolve the binding modes of fragment ligands. 12 On the basis of the detailed information provided by crystal structures, virtual screening has been used successfully to discover fragment ligands with high hit rates for soluble proteins 9, 13 and, more recently, GPCRs. 14, 15 However, as the determination of GPCR crystal structures still requires considerable experimental effort, in silico fragment screening remains limited to the small number of crystallized targets. On the other hand, if homology models based on available templates could be utilized in FBLD, structure-guided discovery and optimization of fragments could be applied to a large fraction of the GPCR superfamily, but this has rarely been attempted. 16, 17 Moreover, access to models of several receptor subtypes may also enable the efficient design of selective leads, which is crucial in drug development to avoid adverse effects caused by interactions with unintended targets.
In this work, we explored the prospect of using in silico screening of commercially available libraries to identify and optimize subtype-selective fragments targeting GPCRs of unknown structure. The target GPCR, the A 3 adenosine receptor (A 3 AR), belongs to a family of four human receptors that recognize adenosine and was selected for its potential as a drug target for a wide range of diseases, including glaucoma (antagonists), cancer (agonists), and asthma (antagonists). 18, 19 As interactions with the closely related A 1 adenosine receptor (A 1 AR) may cause cardiac complications 20 (A 1 agonists) and lead to increased risks for seizure and stroke (A 1 antagonists), 19 fragments that selectively bind to the A 3 AR over the A 1 AR were sought. We generated models of the A 3 AR and A 1 AR based on a crystal structure of the A 2A AR and carried out molecular docking screens of >0.5 million fragments against both receptors. Fragments predicted to bind preferentially to the A 3 AR over the A 1 AR were evaluated in a live-cell fluorescencebased high-content screening assay. To further probe the utility of our approach, the A 1 -and A 3 AR homology models were also used to guide the optimization of fragment potency and selectivity. On the basis of our results, the feasibility of structure-guided FBLD for GPCRs of unknown structure will be discussed.
■ RESULTS
Homology Modeling of the A 3 and A 1 Adenosine Receptors. As no crystal structures of the A 3 -and A 1 AR were available, protocols for the generation of homology models for the target and antitarget receptors were developed. A structure of the A 3 AR binding site was required in order to predict ligands, and modeling of the A 1 AR was essential for assessing the selectivity by comparing differences between the predicted binding energies from molecular docking for the two subtypes. The protocol for optimization of the homology models is summarized in Figure 1 .
Homology modeling of the A 3 -and A 1 AR was based on a high-resolution crystal structure of the closely related A 2A AR, 21 which has 51% and 59% sequence identity to the A 3 -and A 1 AR, respectively, in the transmembrane region ( Figure S1 ). To identify a suitable model of the A 3 AR, a ligand-guided homology modeling approach was employed. 22, 23 Initially, 1000 A 3 AR homology models were generated, and the 300 structures with the highest model quality, as judged by their DOPE scores, 24 were further evaluated. Docking screens of two sets of compounds were used to assess the ability of the A 3 AR models to recognize known ligands. One set of lead-like ligands and one set of >50-fold subtype-selective A 3 AR ligands were compiled, and 50 decoys per ligand were added to each compound set. 25 The lead-like set was first docked to the 300 A 3 AR homology models using DOCK3.6. 26 The ability of a model to enrich ligands over decoys was assessed on the basis of a receiver operator characteristic (ROC) curve and quantified using the adjusted logarithm of area under the curve (aLogAUC) metric. 27 A positive aLogAUC value for a given model indicates that enrichment of ligands over decoys is better than random. The 50 models with the best aLogAUC values, ranging from 31 to 39, were taken forward for further assessment (Figures 1 and S2a ). These binding site models displayed strong enrichment of known ligands and ranked them 26-fold better than expected from random selection in the top 1% of the screened database. The set of A 3 AR-selective ligands together with decoys was then docked to the 50 remaining models. The ligand enrichments for these models were again significantly better than random (aLogAUC = 11−41). The homology model with the best enrichment of lead-like and A 3 AR-selective compounds was also judged to produce binding modes that agreed with those observed for ligands in available crystal structures of the A 2A AR 21 ( Figure 2a ), and this model was taken forward for prospective screening.
As in the case of the A 3 AR, 1000 homology models were also generated for the A 1 AR, and retrospective screens of lead-like ligands along with decoys against 300 structures were carried out to identify suitable binding site structures. The resulting enrichments were again significantly better than random for a majority of the models ( Figure S2b ). The A 3 AR-selective ligand set was then docked to the 50 best models. However, in contrast to the A 3 AR modeling protocol, the goal was to identify A 1 AR structures that did not enrich these compounds to bias the prospective docking screen toward the discovery of Ligand-guided homology modeling was used to identify homology models suitable for virtual screening. In a first step, 1000 homology models for each receptor based on an A 2A AR crystal structure were generated. Docking screens against the 300 homology models with the best model quality scores were then used to identify 50 binding site structures of the A 3 -and A 1 AR with the ability to recognize known (lead-like) ligands. Molecular docking of A 3 AR-selective ligands to the 50 models was used to guide the selection of a single structure for the A 3 AR subtype and an ensemble of 10 A 1 AR structures, which were used in the prospective screens. The A 1 -, A 2A -, and A 3 AR are depicted in cyan, green, and white, respectively.
A 3 AR-selective ligands, i.e., the models with the lowest aLogAUC values were considered. The enrichment of A 3 ARselective ligands was significantly worse for the A 1 AR model compared with the A 3 AR model, indicating that subtype selectivity was captured ( Figure S2b) . However, to ensure that a ligand of the target receptor will not bind to the antitarget, it is not sufficient to screen a single structure, as the compound may be recognized by a different binding site conformation. To take this into consideration, 10 different models representing different shapes of the orthosteric site were selected on the basis of the quality of the binding poses of known A 1 AR ligands and their lower enrichment of A 3 AR-selective ligands ( Figures  S2b and S3) .
Analysis of the A 1 -and A 3 AR models revealed highly similar orthosteric sites, with close to 50% identical amino acid residues in the binding pocket. The predicted binding modes for A 3 AR-selective ligands provided insights into structural elements that could be exploited to achieve subtype selectivity ( Figure 2 The potential importance of these residues for selectivity was further supported by evidence that several docked A 3 ARselective ligands occupied this subpocket with bulky groups. There were also more deeply buried nonconserved residues in the orthosteric site, e.g., Ser247
6.52 of the A 3 AR. As the A 1 AR had His251 6.52 in the corresponding position, this created an additional subpocket in the A 3 AR model that was occluded in the antitarget (Figure 2) . Docking Screen for A 3 AR-Selective Fragments. After deriving homology models of both the A 1 -and A 3 AR subtypes, we turned to prospective screening for novel A 3 AR fragment ligands. We were particularly interested in investigating whether a structure-based approach enables prediction of selective scaffolds, as ligands with specificity for the targets are typically not expected to emerge from fragment screening campaigns. 9 More than 0.5 million commercially available fragments from the ZINC database 29 were screened against the A 3 AR structure and the ensemble of 10 A 1 AR models using DOCK3.6. 26 Each compound in the library was docked in thousands of orientations, resulting in a total of five billion predicted receptor−fragment complexes. A fragment was considered to be selective for the A 3 AR if it was top-ranked for the model of this receptor and the difference in docking rank was >10 000 positions worse for all of the screened A 1 AR models. On the basis of this criterion, only 27 of the 500 top-ranked compounds for the A 3 AR were selective, which likely reflected the high degree of similarity between the binding sites of these AR subtypes. In addition, as only fragments were considered, there were few compounds that could form the key interactions required for ligand binding and extend into nonconserved regions. The 4000 top-ranked compounds from the A 3 AR screen (0.8% of the screened database) had to be considered to identify 500 fragments that fulfilled the selectivity criterion. A large fraction of the 500 molecules interacted with Asn250 6.55 and typically extended into at least one nonconserved region of the orthosteric site. Predicted binding poses were also inspected for the 10 A 1 AR models to ensure that the same receptor− ligand interactions could not be achieved for the antitarget. After visual inspection, a diverse set of 21 compounds (compounds 1−21; Table S1 ) were selected for experimental evaluation on the basis of their shape complementarity to the A 3 AR binding site, taking into account neglected terms in the docking scoring function as described previously.
14,22,30 These compounds were also screened for substructures present in the set of previously characterized pan-assay interference compounds (PAINS) 31 and did not contain any of these motifs. The average ranks for the selected compounds were 2293 for the A 3 AR and 29 579 for the A 1 AR, with a median rank difference of 24 319.
The predicted ligands were evaluated using a live-cell fluorescence-based competition assay at the A 3 -and A 1 AR. This assay uses an image-based approach to measure the ability of each compound to compete with the binding of a xanthine amine congener-based fluorescent ligand, CA200645.
5 Known A 3 AR-selective (MRS1220) or A 1 AR-selective (DPCPX) antagonists were tested on both A 3 AR-and A 1 AR-expressing cells to confirm that each cell line had the expected pharmacology for the given receptor ( Figure S4 ). Compounds were initially evaluated at a single concentration (typically 1 mM), and the nine compounds that displaced the binding of CA200645 at the A 3 AR to within 15% of that achieved by the reference A 3 AR-selective compound MRS1220 (1 μM) were taken forward for further evaluation (Table S1 and Figure S5 ). Full concentration−response curves were generated for compounds 1−9 ( Figure S6 ). The K i values for compounds 1−4 ranged from 0.12 to 1.3 μM at the A 3 AR. Compounds 5− 8 were less potent A 3 AR ligands, and their K i values could not be precisely determined. Compound 9 was found to interfere with the assay and was therefore excluded from further consideration. The eight identified A 3 AR ligands corresponded to a hit rate of 38%, and notably, six of them displayed the desired selectivity. No compounds with significant activity displayed higher affinity for the A 1 subtype over the A 3 subtype (Tables 1 and S1 ). The four most potent compounds (1−4) were further examined, and their predicted binding modes are shown in Figures 3 and S7. Whereas compound 3 displayed similar affinities for the two subtypes, compounds 1, 2, and 4 were remarkably selective for the A 3 AR with K i ratios ranging from 24 to >38. In addition, the ligand efficiencies for the four most potent fragments (calculated as LE = −(RT ln K i )/N, where N is the number of ligand heavy atoms) varied between 0.47 and 0.62 kcal mol
, which indicated that they were promising starting points for optimization. 32 The chemical novelty of compounds 1−4 was assessed on the basis of their two-dimensional similarities to all A 1 -, A 2A -, b Values represent mean ± standard error of the mean (SEM) from n separate experiments performed in duplicate.
c Fold selectivity represents the K i value at the A 1 AR divided by the K i value at the A 3 AR.
d Compound 2 could not be tested at concentrations higher than 100 μM because of solubility issues. The pK i value was derived by assuming that higher concentrations would displace binding to nonspecific levels. A 2B -, and A 3 AR ligands in the ChEMBL20 database. Similarity was quantified using the Tanimoto coefficient (T c ) calculated with extended connectivity fingerprints, maximum distance 4 (ECFP4). The maximal T c value of 1 is obtained if there is an identical known ligand, whereas small values indicate low similarity to previously characterized compounds. The calculated T c values for the identified ligands ranged from 0.28 to 0.4 (Table S2) . Compounds 2−4 were judged to be dissimilar to the most similar AR ligands, and these molecules also had T c values of <0.4, which is typical for novel chemotypes. 33 Compounds 1 and 4 belong to a previously characterized thiazole scaffold, but it should be noted that both A 1 -and A 3 AR-selective compounds bearing this group have been discovered. 34, 35 In fact, none of the discovered selective fragments would have been expected to be A 3 AR-specific on the basis of the K i value of the closest ligand (Table S2 ). The known AR ligand closest to compound 1 (T c = 0.40) was selective for the A 1 AR (rat, 0.039 μM) over the A 3 AR (human, 42% at 1 μM). 36 Furthermore, the ChEMBL ligand most similar to compound 2 was a very close analogue of our reference ligand, the highly selective A 1 AR antagonist DPCPX ( Figure S4 ). Finally, it should be noted that the use of ligandguided homology modeling did not appear to bias the docking screen, as none of the discovered compounds belonged to the class of A 3 AR-specific pyrazolotriazolopyrimidines 37 that constituted the main selective scaffold used to guide model selection (Figure 2a) .
Fragment-to-Lead Optimization. Although the successful identification of fragment ligands for the A 3 AR was encouraging, a requisite for successful FBLD is the optimization of these in terms of selectivity and potency.
1 Fragment-to-lead optimization was guided by the receptor models and focused on the structure−activity relationship (SAR) for the two most potent and selective fragments, 1 and 2. Five analogues of compound 1 and six of compound 2 were tested at the A 3 -and A 1 AR in the fluorescence-based competition binding assay (Tables 2 and 3 (Figure 3a ). These two groups were connected via a 1,3-thiazole-2-carboxamide moiety, which formed hydrogen bonds to Asn250 6.55 and π-stacking interactions with Phe168 5.29 . Despite the fact that this ligand has only 16 heavy atoms, 29-fold selectivity was observed experimentally. Compound 22 was first evaluated to assess the role of the furan group, which extended into the nonconserved hydrophobic pocket in the top of the orthosteric site. The predicted binding mode of compound 22 suggested that the slightly smaller substituent would not access the nonconserved pocket to the same extent as compound 1 (Figure 4a ). The significant loss of A 3 AR affinity and specificity for compound 22 supported the importance of the furan group (Table 2) . To further optimize the ligand from a fragment to a lead-like compound, commercially available analogues with larger substituents were docked to the A 3 AR model. Compound 23, with a benzothiophene group replacing the furan, extended further into the hydrophobic pocket at the top of the A 3 AR orthosteric site (Figure 4b ). In agreement with this observation, this ligand was 3-fold more potent at the A 3 AR, which resulted in an overall 100-fold selectivity for this subtype (Table 2 and Figure 5a ). Focus was then put on optimizing interactions in the nonconserved regions in the bottom of the A 3 AR binding site, which was predicted to accommodate the cyclopropyl group. In compounds 24 and 25, the cyclopropyl-substituted thiazole is replaced by 5,6-dihydro-4H-cyclopentathiazole and benzothiazole groups, respectively. Interestingly, these ligands displayed >10-fold lower affinity for the A 3 AR compared with the parent compound, leading to a loss of selectivity ( Table 2) . Analysis of the docking poses suggested that the bicyclic substituents did not penetrate as deep as the cyclopropyl group into the nonconserved pocket below Asn250 6.55 of the A 3 AR (Figures 4 and S8) . Instead of reverting to the more potent cyclopropyl group, we evaluated compound 26, which was predicted to position a methoxy group in the same pocket. This analogue restored the affinity (K i = 120 nM) and improved the selectivity (34-fold) toward the A 3 AR (Figure 4c and Table 2 ). Overall, 3-fold improvements of potency and selectivity were achieved in the optimization, and the most promising lead was compound 23, which had a K i value of 40 nM and >100-fold selectivity for the A 3 AR over the A 1 AR (Figure 4d) .
Compound 2 was the most promising fragment in terms of selectivity and also had a high LE (0.47 kcal mol
). On the basis of its predicted binding mode, the selectivity appeared to originate from the pyrrolidine ring in the nonconserved pocket at the opening of the A 3 AR binding site (Figure 3b) . To investigate the contribution of this substituent to the selectivity, an analogue that lacked this group (compound 27) was evaluated. As anticipated, this fragment lost a majority of its selectivity (Table 3 ). Our models thus suggested that both compounds 1 and 2 achieved their selectivity by interacting with residues in the same nonconserved subpocket (Figure 2 ). This led us to hypothesize that the SAR for analogues of compound 1 may be transferable to this scaffold. On the basis of this observation, the pyrrolidine was replaced by a furan group in compound 28, which docked well into the A 3 AR model ( Figure S9a ). Compound 28 displayed 5-fold-improved potency at the A 3 AR and remained strongly selective for this subtype (Table 3 and Figure 5b ). Compounds 29 and 30 were then tested to further investigate the SAR for substituents at the same position. Increasing the size of the substituent to a pyridine in compound 29 led to a 4-fold loss of A 3 AR affinity compared with compound 28, which decreased the selectivity, while reducing the size to a nonplanar cyclopropyl moiety in compound 30 retained significant specificity toward the A 3 AR (70-fold) ( Table 3) . Focus was then put on further exploring the SAR for the most promising fragment, compound 28, by evaluating analogues that retained the furan moiety. Compound 31 maintained its affinity at the A 3 AR but was also 30-fold more potent at the A 1 AR, which significantly reduced the selectivity (Table 3) . Similarly, compound 32, which was evaluated in order to extend further toward the second nonconserved pocket around Ser247 6.52 , was almost equally potent at both subtypes (Table 3) . These results supported the conclusion that in addition to the furan group, the ethyl substituent of compound 28 was also important for A 3 AR specificity. This further demonstrated that effects on the selectivity due to substituents at one position can strongly depend on substituents at other positions of a fragment ligand, which is in line with observations made for analogues of compound 1. This could be due to the ability of certain substituents to anchor the core scaffold of a fragment in a particular orientation, resulting in selectivity when nonconserved binding site regions are targeted by other substituents. However, in the absence of such an anchoring group, selectivity gained by the other substituent could be reduced or ablated because the fragment can reorient in the binding site. Visual inspection of the docking poses for compounds 28 and 31 further supported this hypothesis. In contrast to the selective parent compound 28, compound 31 could be better accommodated in seven out of the 10 A 1 AR models (and equally well in the remaining three), as judged by key interactions with Asn 6.55 . Anchored by the ethyl substituent, the orientation of compound 28 appeared to be more restricted in the A 1 AR binding site, whereas compound 31 was able to reorient in response to the subtle change in chemical structure ( Figure S9) . Overall, the best ligand emerged from optimization of interactions in the nonconserved cavity at the top of the binding site, and despite the fact that compound 28 was still fragment-sized, it had submicromolar affinity with >100-fold A 3 AR selectivity.
To further probe the selectivity profiles of our discovered ligands, the two most promising leads, compounds 23 and 28, and the fragment ligands from which they were derived, compounds 1 and 2, were evaluated in radioligand binding assays at the A 2A AR. Compounds 1, 2, and 28 did not show any significant displacement of the radioligand at 10 μM, whereas compound 23 was determined to have a K i value of 2.9 μM, resulting in 72-fold selectivity for the A 3 AR over the A 2A subtype. All four of these compounds were thus selective for the A 3 AR over both the A 1 and A 2A subtypes.
Functional Assays for Compounds 23 and 28. As the A 3 AR homology model was based on a crystal structure determined in an inactive state and a recent study demonstrated that commercial screening libraries are biased toward AR antagonists over agonists, 38 we expected the discovered ligands to behave as antagonists. This was confirmed by evaluating the functional behavior of our most promising leads, compounds 23 and 28, for their ability to antagonize 5′-N-ethylcarboxamidoadenosine (NECA)-mediated internalization of the A 3 AR linked to yellow fluorescent protein (YFP). Both ligands caused a rightward shift in the agonist-mediated concentration response curve ( Figure 6 ) with no increase in internalization at low NECA concentrations, indicating competitive antagonism. From these shifts, the affinities (pK D ) of the antagonists 23 and 28 were estimated to be 6.13 ± 0.01 and 6.13 ± 0.08 (mean ± SEM, n = 5), respectively.
■ DISCUSSION
Three key results emerge from our study. Fragment ligands were first successfully identified on the basis of molecular docking screens against a homology model of the A 3 AR. Eight out of the 21 predicted ligands were verified to bind in a livecell environment using fluorescent ligand assays, corresponding to a high hit rate of 38%, and several fragments had high affinities. The second and perhaps most important finding in this work is that an additional screen against homology models of an antitarget could be used to bias the screen toward the identification of subtype-selective fragments. Despite the low molecular complexity of the screened fragments, six of the eight discovered ligands were selective for the A 3 AR over the A 1 AR, and several displayed remarkably large differences in potency. Finally, the homology models contributed to an understanding of the structural basis for the selectivity and were used to guide fragment-to-lead optimization.
It could be argued that prediction of fragment ligands should pose a significant challenge to molecular docking algorithms. As fragments only occupy a fraction of a binding site, they can be docked in a large number of orientations, and it may be difficult for the simplified scoring function to rank these by affinity. Despite these shortcomings of docking, the first virtual screens of fragment libraries against GPCR crystal structures have been successful, reaching hit rates as high as 73% for the H 1 histamine receptor. 14, 15 The high hit rates achieved in these studies partly reflect the druggability of the orthosteric sites of GPCRs and favorable library bias, 39 making these targets particularly suitable for fragment screening. In addition to the higher hit rates observed for fragments and the lower computational cost of the in silico screens, there are other advantages of focusing on such libraries. For example, as fragment libraries offer better coverage of chemical space, docking screens of these may lead to the discovery of chemotypes that are not present in lead-like libraries. 13 The present study involved additional layers of complexity wherein fragment ligands were sought to a receptor of unknown structure and were required to be less potent at a closely related subtype also lacking a crystal structure. To put our results in perspective, Stoddart et al. 5 carried out an empirical screen of 248 fragments against the A 3 AR using the same fluorescent binding assay as in this work, which resulted in the discovery of 34 ligands with affinities between 0.4 and 107 μM. The 14% hit rate from the screen was relatively high compared with other experimental fragment screens against GPCRs, 2,3 and 17 of the ligands had K i values of <10 μM. The most potent fragment (K i = 360 nM) was also tested for A 3 AR selectivity and was found to display similar affinity for the A 1 AR. The docking screen carried out here considered a 2000-fold larger library (>0.5 million compounds) but required the experimental evaluation of only 21 compounds. The eight discovered A 3 AR ligands corresponded to a nearly 3-fold higher hit rate, and a larger fraction of the hits (four compounds) had K i values of <10 μM. Notably, the most potent fragment from the docking screen had a K i value of 120 nM with 29-fold selectivity for the A 3 AR. Overall, the most potent fragments identified by molecular docking and those from Stoddart et al. had similar novelty but did not significantly overlap in terms of chemotypes. This result further supports the conclusion that combining empirical screens of small libraries with in silico screening of all commercially available fragments can increase the number and diversity of starting points for optimization. 14, 40 Accurate approaches for homology modeling will be required to fully capitalize on the recent advances in membrane protein crystallography and may prove to be essential for addressing key challenges in early-phase drug discovery. 41 A particularly important role of homology models is in structure-based design of selective ligands, as representative crystal structures for all receptor subtypes are not available for any human GPCR family. 11 Prospective docking screens against homology models of GPCRs have to date yielded different levels of success 16, 22, 30, 42 and to our knowledge have not previously involved modeling of both a target and antitarget to drive structure-based discovery of selective fragments. If a crystal structure of a receptor closely related to the target is available, it could be argued that homology models should be suitable for docking screens because subpockets that are conserved are likely to be well-described. In such cases, minor discrepancies in nonconserved regions of the binding site may not influence the docking hit rate. On the contrary, structure-based screens for selective ligands generally involve interactions in regions that are not conserved, which are difficult to model accurately on the basis of homology. 42, 43 This problem was recently highlighted by the work of Rodriguez et al., 43 which demonstrated that homology models of the serotonin 5-HT 1B and 5-HT 2B receptors lacked the accuracy required to capture the subtle binding site differences responsible for subtype selectivity that were revealed by crystal structures of these GPCRs. In the light of these results, it was clear that tailored modeling strategies for both the target and antitarget receptors would be necessary to predict subtype-selective GPCR ligands. We used ligand-guided homology modeling to bias the A 3 AR model toward a conformation with the ability to recognize selective scaffolds using an approach similar to that of Katritch et al. 23 A unique component of our strategy was a representation of the antitarget that captured binding site flexibility by using an ensemble of structures 44 optimized to discriminate between selective and non-A 3 AR-selective ligands. Our docking screens against the resulting A 3 -and A 1 AR models led to the discovery of eight fragment ligands, of which six displayed the desired subtype selectivity. However, despite the use of 10 different antitarget models, two fragment hits were only marginally more potent at the A 3 AR than at the A 1 subtype, suggesting that additional and more disparate conformations might need to be considered in order to further improve predictions of selectivity. Furthermore, we have not explicitly considered binding site water molecules, which could play important roles in determining ligand specificity. 45−47 The use of ligand data to generate the homology models is also a limitation of our approach, but it should be noted that the amount of publicly available small-molecule binding data for GPCRs is increasing rapidly. 48 Our approach is highly automated, and we anticipate that it could be extended to a large number of GPCR families, including many targets for which drug discovery has been hampered by adverse effects caused by off-target interactions.
Efficient optimization of fragment hits is crucial for the successful use of FBLD in drug discovery.
1, 7 The discovery of several ligands in our screen provided the opportunity to test whether homology models could guide fragment-to-lead optimization. Whereas potency (or ligand efficiency) is typically used to prioritize hits from fragment screens, 32 opinion is currently divided regarding whether selectivity should be considered. It has been argued that selectivity is too challenging to predict and that this property may be lost (or gained) in fragment-to-lead optimization. 49 As previously observed for kinases, 49 a complex SAR was observed in the optimization of selectivity, and small structural changes greatly affected the specificity, which may reflect the fact that fragments can reorient in the binding site during optimization to a larger extent than leads. 50 This likely makes rational optimization more challenging for fragment ligands than for lead-or druglike molecules. Encouragingly, we found that the associated differences in selectivity could be explained by the homology models in several cases and guide further optimization. Our results suggest that selectivity can be a valuable property of hits from fragment screens provided that the structural basis of
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Article ligand binding is understood and systematically utilized to guide optimization. For two selective fragments identified in our screen, the chemical groups responsible for the subtype selectivity were first predicted on the basis of modeled receptor−fragment complexes and subsequently confirmed experimentally by evaluating analogues lacking those moieties. Compounds that further exploited nonconserved pockets were then identified using docking to the A 3 AR models, which led to the discovery of potent lead compounds with >100-fold selectivity and up to 40 nM affinity for the A 3 AR. Interestingly, the two optimized leads, compounds 23 and 28, and the fragments from which they were derived were also selective for the A 3 AR over the A 2A AR, which may reflect binding site similarities between the A 1 and A 2A subtypes.
■ CONCLUSIONS
The main finding of this work is that docking screens against homology models of GPCRs can be utilized to discover subtype-selective fragments. The structural understanding of ligand selectivity gained from the homology models can also be used to guide fragment-to-lead optimization. The described strategy for in silico FBLD for GPCRs of unknown structure can be readily extended to a large number of pharmaceutically important targets.
■ METHODS
Sequence Alignment and Homology Modeling. The sequences of the human A 3 -and A 1 AR were aligned to that of the template crystal structure, the human A 2A AR, using PROMALS3D. 51 The sequence alignment was manually edited in loop regions. The Cand N-terminals and the third intracellular loop were excluded from the modeling because they were missing in the template structure. Homology modeling of the human A 3 AR and A 1 AR was performed on the basis of a 1.8 Å resolution structure of the A 2A AR (PDB accession code 4EIY 21 ) using MODELER version 9.11. 52 A total of 1000 models were generated for each receptor. Additional dihedral restraints were placed on the conserved Asn 6.55 to keep the rotamer of this residue close to that observed in a majority of the available A 2A AR crystal structures. For the A 3 AR, restraints were placed on the side-chain rotamer of nonconserved Ser247 6.52 to keep it similar to the template and the distance between residues Arg173 5.34 and Asp175 5.36 to prevent these residues from blocking the orthosteric site. For the A 1 AR, additional dihedral and distance restraints were placed on Glu172 5.30 and His264 6.66 to maintain the salt bridge observed in the template crystal structure of the A 2A AR and on Lys265 6.67 to prevent it from blocking the orthosteric site.
Ligand-Guided Homology Modeling and Molecular Docking Screening. All of the docking calculations were carried out with the program DOCK3.6. 26 Unless stated otherwise, the protonation states of the ionizable residues Asp, Glu, Arg, and Lys in the binding site were set to their most probable states in the receptor at pH 7. Histidine tautomeric states in the binding site were set on the basis of the hydrogen-bonding network. His251 6.52 , His264 6.66 , and His278 7.43 in the A 1 AR were protonated at Nε, both side-chain nitrogens, and Nδ, respectively. Of these, only His272 7.43 was also present in the A 3 AR and was protonated in the Nδ position. The flexible ligand sampling algorithm in DOCK3. 6 26 superimposes atoms of the docked molecule onto binding site matching spheres, which indicate putative ligand atom positions. A total of 45 matching spheres were used and were based on the atoms of the cocrystallized antagonist ZM241385. The spheres were also labeled for chemical matching based on the local receptor environment. 53 The degree of ligand sampling was determined by the bin size, bin size overlap, and distance tolerance. These three parameters were set to 0.4 Å, 0.2 or 0.3 Å, and 1.5 Å, respectively, for both the binding site matching spheres and the docked molecules. An initial filter discarded conformations that had more than one overlapping heavy atom with the receptor. An overlap between two atoms was defined as a distance shorter than 2.3 or 2.6 Å for polar or nonpolar atoms, respectively, and was determined from a precalculated grid. For ligand conformations passing this steric filter, a physics-based scoring function was used to evaluate the fit to the binding site. For the best-scoring conformation of each docked molecule, 100 steps of rigid-body minimization were carried out. The score for each conformation was calculated as the sum of the receptor−ligand electrostatic and van der Waals interaction energies, corrected for ligand desolvation. These three terms were evaluated from precalculated grids. The three-dimensional map of the electrostatic potential in the binding site was prepared using the program Delphi. 54 In this calculation, partial charges from the united-atom AMBER force field 55 were used for all receptor atoms except the sidechain amides of Asn250 6.55 and Asn254 6.55 for the A 3 AR and A 1 AR, respectively, for which the dipole moment was increased to favor hydrogen bonding to this residue, as described previously for the A 2A AR. 14, 39 The program CHEMGRID was used to generate a van der Waals grid based on a united-atom version of the AMBER force field.
55
The desolvation penalty for a ligand conformation was estimated from a precalculated free energy for transfer of the molecule between solvents with dielectric constants of 78 and 2. The desolvation energy was obtained by weighting the transfer free energy with a scaling factor that reflects the degree of burial of the ligand in the receptor binding site. 27 Sets of lead-like ligands (molecular weight <350) for the A 3 AR and A 1 AR were extracted from the CHEMBL14 database 48 and consisted of 520 and 622 compounds, respectively. The set of 138 subtypeselective ligands of the A 3 AR (molecular weight <500, >50-fold selective for the A 3 AR over the A 1 subtype) was extracted from CHEMBL14. 48 Decoys were generated in a 1:50 ratio for each of the three ligand sets using the DUD-E approach. 25 In the prospective screens, the ZINC fragment library 29 of 504 973 commercially available compounds (molecular weight ≤250, LogP ≤ 3.5, and ≤5 rotatable bonds) was used. All of the docked compounds were prepared for docking using the ZINC database protocol. 29 Similarity Calculations. Similarity calculations for the fragments were carried out using the Screenmd program from Chemaxon. 56 We calculated the maximum Tanimoto coefficient with ECFP4 fingerprints between each discovered fragment ligand and all compounds that have been annotated against any AR subtype in the ChEMBL20 database. 48 Materials. The fragment hits from the initial screen and the analogues of compounds 1 and 2 were purchased from Enamine, Life Chemicals, VitasM, Peakdale, Chembridge, and UK organic synthesis (Table S3) . Compound identities and purities were confirmed by NMR and liquid chromatography−mass spectrometry (LC−MS) for all discovered ligands (Table S3) . FCS was purchased from PAA Laboratories (Wokingham, UK) and L-glutamine from Lonza (Basel, Switzerland). MRS1220, DPCPX, and NECA were obtained from Tocris Bioscience (Bristol, UK). CA200645 was purchased from Cellaura Technologies Ltd. (Nottingham, UK). All other chemicals and reagents were purchased from Sigma-Aldrich (Gillingham, UK).
Cell Lines and Cell Culture. Chinese hamster ovary (CHO) cells expressing the A 1 AR 57 and CHO CRE-SPAP cells expressing the A 3 AR 58 or A 3 -YFP 59 were prepared as previously described. All of the cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM) nutrient mix F12 (DMEM-F12) supplemented with 10% fetal calf serum and 2 mM L-glutamine at 37°C in a humidified atmosphere of air/CO 2 .
Fluorescence-Based Competition Binding Assay. Cells expressing the A 1 AR or A 3 AR were grown to confluency in the central 60 wells of a 96-well plate in normal growth medium. Because of issues with the quality of the images obtained from the outside wells of a 96-well plate, the outer wells were left blank. On the day of analysis, the medium was removed and the cells were washed twice with HEPES-buffered saline solution (HBSS; 25 nM HEPES, 10 mM glucose, 146 mM NaCl, 5 mM KCl, 1 mM MgSO 4 , 2 mM sodium pyruvate, 1.3 mM CaCl 2 , 1 mM NaHCO 3 , pH 7.4). For initial evaluation of compounds 1−21, a single concentration of test compound (dependent on the solubility of the individual compound; see Figure S5 and Table S1 ), 1 μM MRS1220, 1 μM DPCPX, or buffer was added in duplicate to the required wells, followed by 25 nM CA200645. For analysis of the affinities of compounds, increasing concentrations of the required compounds were added, followed by 25 nM CA200645. Cells were then incubated for 1 h at 37°C (no CO 2 ) and then washed once in HBSS prior to imaging on an ImageXpress Ultra confocal plate reader (Molecular Devices, Sunnyvale, CA, USA). Four images were taken per well using a Plan Fluo 40× NA0.6 extralong working distance objective by excitation of the fluorophore (BODIPY630/650) at 636 nm, and the emission was collected through a 640−685 nm band-pass filter. To obtain the total image intensity a modified multiwavelength cell scoring algorithm within MetaXpress software (Molecular Devices) was used.
Receptor Internalization Assay. CHO cells expressing A 3 -YFP were grown to confluency in the central 60 wells of black-walled, clear bottom 96-well plates. On the day of the experiment, normal growth medium was replaced with serum-free medium (DMEM-F12 containing 2 mM L-glutamine) containing, where required, a fixed concentration of 23 or 28, and the cells were incubated for 30 min at 37°C/5% CO 2 /95% air. This was followed by the addition of increasing concentrations of NECA, and the cells were incubated for a further 60 min. All of the medium was then removed, and the cells were washed once in phosphate-buffered saline (PBS) prior to fixation with 3% paraformaldehyde solution in PBS (20 min, room temperature). The cells were then washed twice in PBS, and the nuclei were stained by the addition of H33342 (2 μg/mL −1 , 20 min, room temperature). The cells were washed a further two times and then imaged on the ImageXpress Ultra confocal plate reader. Four central images were taken per well using a Plan Fluor 40× NA0.6 extra-long working distance objective. YFP images were obtained by excitation at 488 nm, and the emission was collected through a 525− 550 nm band-pass filter. H33342 was imaged by excitation at 405 nm and emission collection through a 447−460 nm band-pass filter. Analysis of the images was carried out using a granularity algorithm within MetaXpress software (Molecular Devices) to identify the granule count per cell on a per-image basis. A 3 -YFP granules were classified as having a diameter of between 7 and 15 μm and cell nuclei between 6 and 9 μm, with the intensity above background set for each individual experiment.
Data Analysis. All of the concentration−response data were fitted using nonlinear regression models with Prism 6 (GraphPad Software, San Diego, CA, USA). Competition binding curves were fitted to the following equation to obtain the binding affinity (K i ) of the unlabeled ligand to the receptor: where E max is the maximal response in the absence of competing ligand and the EC 50 is the molar concentration of agonist required to generate 50% of the E max . This was followed by estimation of the affinity (K D ) of the competing ligand using the Gaddum equation: 
